Addressing New Concepts and Practical Challenges in MS
Released On
June 15, 2023
Expires On
June 15, 2024
Media Type
Internet
Completion Time
60 minutes
Specialty
Neurology, Primary Care
Topic(s)
Multiple Sclerosis
This activity is provided by The Consortium of Multiple Sclerosis Centers (CMSC) and The France Foundation (TFF).
This activity is supported in part by an independent education grant from Novartis.
Credit Available
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
- Nurses — 1.0 Contact Hours
- Phamacists — 1.0 Contact Hours (0.1CEUs) of continuing pharmacy education credit
- Physician Assistants — maximum of 1.0 AAPA Category 1 CME credit
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This activity is designed to meet the educational needs of neurologists, MS subspecialists, primary care clinicians, advanced practice clinicians, nurses, pharmacists, and other members of the comprehensive MS care team.
Program Overview
The landscape of MS is constantly changing as new science and innovation make strides towards improving disease management and quality of life. In this module you will first listen to an interprofessional panel of MS experts discuss the latest in MS treatment, including available options and treatment strategies. Then, dive deeper with a discussion of viruses and other risk factors contributing to the development of MS.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Explain the most recent advances in the understanding of MS immunology based on the latest science in order to initiate and sustain appropriate treatments
- Identify comorbid risk factors for MS progression in order to apply appropriate strategies
- Review efficacy and safety data for current and emerging DMT agents for MS
Faculty
Lisa Fox, PA-C
Senior Physician Associate
Department of Neurology
Associate Director, Neurology Outpatient Infusion Center
Johns Hopkins Medicine
Baltimore, MD
Michael Levy, MD, PhD
Associate Professor, Harvard Medical School
Director, Neuroimmunology Clinic and Research Laboratory
Research Director, Division of Neuroimmunology & Neuroinfectious Disease
Department of Neurology, Massachusetts General Hospital
Boston, MA
Scott Newsome, DO, MSCS, FAAN, FANA
Associate Professor of Neurology
Director, Neurosciences Consultation and Infusion Center at Green Spring Station
Director, Stiff Person Syndrome Center
Director, Johns Hopkins Neuroimmunology Clinical Fellowship Program
Co-director, Multiple Sclerosis Experimental Therapeutics Program
Member, Miller-Coulson Academy of Clinical Excellence
Johns Hopkins University
Baltimore, MD
Jiwon Oh, MD, PhD
Associate Professor
University of Toronto
Toronto, Ontario, Canada
Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Consortium of Multiple Sclerosis Centers (CMSC) and The France Foundation. The CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Credit Designation
The Consortium of Multiple Sclerosis Centers designates this enduring activity for a maximum of 1.0 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses Credit Designation
The Consortium of Multiple Sclerosis Centers designates this activity for 1.0 nursing continuing professional development (NCPD) credits (1.0 of these credits are in the area of pharmacology).
Physician Assistants Credit Designation
The France Foundation has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until 6/15/24. PAs should only claim credit commensurate with the extent of their participation.
Pharmacists Credit Designation
This knowledge-based activity, UAN JA4008165-9999-23-022-H01-P, qualifies for 1.0 contact hours (0.1 CEUs) of continuing pharmacy education credit. Please submit all evaluations and credit requests no later than 30 days after you complete this activity to ensure your credit fulfillment, as CE credit cannot be awarded past 60 days from the activity date. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service custserv@nabp.net.
Disclosures of Conflicts of Interest
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form.
Certificates will be emailed to the participant.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
CMSC and TFF require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. CMSC and TFF do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
Disclaimer
The Consortium of Multiple Sclerosis Centers and The France Foundation present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The Consortium of Multiple Sclerosis Centers, The France Foundation, and the commercial supporter(s) assume no liability for the information herein.
Contact Information
For CME questions please contact: info@francefoundation.com.